Abstract
  • Population : Immunocompetent children aged 3–24 months
  • Intervention: One or two doses of MenA conjugate vaccine (5 µg dosage)
  • Comparison: No MenA vaccination
  • Outcome : Serious adverse events following immunization

What is the incidence of serious adverse events following any dose of MenA conjugate vaccine in immunocompetent children aged 3–24 months?

  • GRADE table
  • Newborn (0-1 years)
  • GRADE
  • meningitis A
  • Meningococcal disease